PFE R&D to Revenue
Pfizer · R&D to Revenue
PFE R&D to Revenue
Latest reported18.68%period ending
PFE Quarterly R&D/Revenue (0.00% → 18.68%)
Latest values, visible window
High-resolution chart · PNG
PFE r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 18.6843% | |
| 18.1787% | |
| 19.468% | |
| 23.634% | |
| 16.6724% | |
| 15.8877% | |
| 16.9847% | |
| 14.4899% | |
| 20.1461% | |
| 16.6678% | |
| 19.0323% | |
| 19.8799% | |
| 20.2122% | |
| 13.4913% | |
| 14.8827% | |
| 11.9092% | |
| 10.1471% | |
| 8.9669% | |
| 24.8133% | |
| 11.1546% | |
| 11.8472% | |
| 13.7366% | |
| 28.8121% | |
| 22.3703% | |
| 21.0361% | |
| 16.632% | |
| 22.1784% | |
| 17.9811% | |
| 13.8043% | |
| 12.9288% | |
| 17.4585% | |
| 15.0323% | |
| 13.2927% | |
| 13.4589% | |
| 16.8138% | |
| 14.0492% | |
| 13.7717% | |
| 13.3109% | |
| 18.3606% | |
| 14.3503% | |
| 13.2958% | |
| 13.3103% | |
| 16.7153% | |
| 14.2467% | |
| 14.6292% | |
| 17.3509% | |
| 24.4626% | |
| 14.5781% | |
| 13.7712% | |
| 14.2958% | |
| 13.3574% | |
| 12.8688% | |
| 11.7937% | |
| 13.3333% | |
| 14.1757% | |
| 14.1743% | |
| 11.2838% | |
| 13.4502% | |
| 15.5022% | |
| 12.7261% | |
| 13.1712% | |
| 12.6712% | |
| 15.9786% | |
| 13.5675% | |
| 12.6219% | |
| 13.2896% | |
| 17.4215% | |
| 14.0435% | |
| 15.6136% | |
| 15.6897% | |
| 18.6538% | |
| 15.7438% | |
| 16.2091% | |
| 15.1165% | |
| 17.5602% | |
| 16.6722% | |
| 19.5327% | |
| 13.3478% | |
| 19.1383% | |
| 15.4886% | |
| 14.8369% | |
| 12.5434% | |
| 14.8679% | |
| 14.6279% | |
| 15.0905% | |
| 13.4749% | |
| 15.6001% | |
| 14.7144% | |
| 14.8199% | |
| 13.2057% | |
| 16.3631% | |
| 15.0272% | |
| 17.182% | |
| 14.2874% | |
| 20.2196% | |
| 14.4756% | |
| 15.648% | |
| 14.267% | |
| 16.7774% | |
| 15.0418% |